A recent Bloomberg article discussed a move by the French that will likely rock the boat of the homeopathic industry. Following a review of homeopathic medicines, France has decided to stop funding products made by Boiron and rival companies at the beginning of 2021. Boiron’s CEO said that sales of reimbursed treatments could drop 50% in France, a market that accounts for nearly half the company’s revenue.
Boiron’s homeopathic products have long been a staple of health care in France, where they’re prescribed alongside conventional products. France’s state health system currently covers about 30% of the cost of homeopathic products. This number will fall to 15% next year as a transition to the end of reimbursement at the start of 2021.